IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Key Points

• IQ EQ FUND MANAGEMENT IRELAND Ltd has increased its position in Intellia Therapeutics, Inc. by 94.3%, now owning 106,209 shares valued at approximately $755,000.
• Intellia Therapeutics stock saw a 5.5% increase, with its current share price at $12.12, and it has a market cap of $1.26 billion.
• Analysts have mixed ratings for Intellia Therapeutics, with one firm setting a target price as high as $68.00, while others maintain lower expectations, reflecting a consensus rating of "Moderate Buy."

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 106,209 shares of the company's stock after purchasing an additional 51,552 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd owned 0.10% of Intellia Therapeutics worth $755,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in Intellia Therapeutics by 30.6% during the first quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 81,000 shares of the company's stock worth $576,000 after acquiring an additional 19,000 shares during the period. Privium Fund Management B.V. lifted its holdings in shares of Intellia Therapeutics by 111.9% in the first quarter. Privium Fund Management B.V. now owns 58,709 shares of the company's stock worth $417,000 after acquiring an additional 31,000 shares during the last quarter. Harbour Investments Inc. lifted its holdings in shares of Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after acquiring an additional 2,264 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of Intellia Therapeutics by 84.2% in the first quarter. XTX Topco Ltd now owns 80,897 shares of the company's stock worth $575,000 after acquiring an additional 36,989 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in shares of Intellia Therapeutics by 154.7% in the first quarter. GSA Capital Partners LLP now owns 219,918 shares of the company's stock worth $1,564,000 after acquiring an additional 133,577 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the completion of the sale, the executive vice president owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. This trade represents a 6.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 12,534 shares of company stock valued at $153,837. Company insiders own 3.10% of the company's stock.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA traded down $0.67 during mid-day trading on Friday, hitting $10.79. The company had a trading volume of 4,068,676 shares, compared to its average volume of 4,629,778. The firm has a fifty day moving average price of $10.55 and a 200 day moving average price of $9.51. The company has a market capitalization of $1.12 billion, a PE ratio of -2.30 and a beta of 2.31. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $24.16.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 54.90%. The business had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. During the same quarter last year, the firm posted ($1.52) EPS. Intellia Therapeutics's revenue was up 104.3% compared to the same quarter last year. Research analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Canaccord Genuity Group dropped their target price on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a report on Tuesday, June 3rd. Royal Bank Of Canada dropped their target price on shares of Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating for the company in a report on Friday. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective for the company in a report on Monday, April 21st. Citigroup dropped their price objective on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Finally, Guggenheim dropped their price objective on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a report on Monday, May 12th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Intellia Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $31.11.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.